MetLife Investment Management’s Bionano Genomics BNGO Stock Holding History

MetLife Investment Management’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-265	Closed	-$176K	–	2945
2023 Q1	$176K	Buy	265 +61	+30%	+$54.2K	﹤0.01%	2293
2022 Q4	$179K	Sell	204 -52	-20%	-$65.4K	﹤0.01%	2315
2022 Q3	$282K	Hold	256	–	–	﹤0.01%	2068
2022 Q2	$212K	Buy	256 +76	+42%	+$78.2K	﹤0.01%	2274
2022 Q1	$278K	Buy	180 +6	+3%	+$8.1K	﹤0.01%	2138
2021 Q4	$311K	Buy	174 +29	+20%	+$77.6K	﹤0.01%	1792
2021 Q3	$477K	Sell	145 -25	-15%	-$87.4K	﹤0.01%	1547
2021 Q2	$750K	Buy	+170	New	+$671K	0.01%	1337

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MetLife Investment Management's BNGO Position: Q2 2023 in Review

MetLife Investment Management sold out of Bionano Genomics (BNGO) in Q2 2023, closing a stake of 265 shares — an estimated $176K sold.

MetLife Investment Management first reported a position in BNGO in Q2 2021 and held it in 8 quarters. The position peaked at $750K in Q2 2021. 108 funds tracked by Wall St. Rank hold BNGO as of Q2 2023.

MetLife Investment Management reported no remaining Bionano Genomics position as of Q2 2023 after selling out during the quarter.
MetLife Investment Management sold 265 Bionano Genomics shares in Q2 2023, an estimated $176K.
MetLife Investment Management first reported a position in Bionano Genomics in Q2 2021 and held it in 8 quarters.
MetLife Investment Management's Bionano Genomics position peaked at $750K in Q2 2021.
108 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2023.

Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.